Table 3.
Patients and disease characteristics, treatment, and compliance by Housing value Index (HI) categories.
| Overall (N/%) N = 15,532 | HI(high) 4251 (27.3%) | HI(med) 10,343 (66.6%) | HI(low) 938 (6.0%) | P value | |
|---|---|---|---|---|---|
| Median follow-up (Inter Quartile Range) | 7.6 years | 7.63 years (4.26–11.60) | 7.69 years (4.56–11.22) | 8.01 years (4.53–12.04) | |
| Age | |||||
| <40yrs | 1381 (8.9%) | 363 (8.5%) | 961 (9.3%) | 57 (6.1%) | <0.0001 |
| 40 to 50yrs | 4457 (28.7%) | 1232 (29.0%) | 3050 (29.5%) | 175 (18.7%) | |
| 50 to 60yrs | 4874 (31.4%) | 1290 (30.3%) | 3299 (31.9%) | 285 (30.4%) | |
| 60 to 70yrs | 3125 (20.1%) | 860 (20.2%) | 1998 (19.3%) | 267 (28.5%) | |
| ≥70yrs | 1695 (10.9%) | 506 (11.9%) | 1035 (10.0%) | 154 (16.4%) | |
| Race | |||||
| Chinese | 12,753 (82.1%) | 3638 (85.6%) | 8418 (81.4%) | 697 (74.3%) | <0.0001 |
| Indian | 816 (5.3%) | 222 (5.2%) | 534 (5.2%) | 60 (6.4%) | |
| Malay | 1519 (9.8%) | 227 (5.3%) | 1131 (10.9%) | 161 (17.2%) | |
| Others | 444 (2.9%) | 164 (3.9%) | 260 (2.5%) | 20 (2.1%) | |
| Stage | |||||
| 0 | 1944 (12.5%) | 652 (15.3%) | 1201 (11.6%) | 91 (9.7%) | <0.0001 |
| I | 4214 (27.1%) | 1384 (32.6%) | 2631 (25.4%) | 199 (21.2%) | |
| II | 5272 (33.9%) | 1360 (32.0%) | 3588 (34.7%) | 324 (34.5%) | |
| III | 2795 (18.0%) | 583 (13.7%) | 2002 (19.4%) | 210 (22.4%) | |
| IV | 1307 (8.4%) | 272 (6.4%) | 921 (8.9%) | 114 (12.2%) | |
| MediFund | |||||
| Never received | 13,074 (84.2%) | 4019 (94.5%) | 8470 (81.9%) | 585 (62.4%) | <0.0001 |
| Ever received | 2458 (15.8%) | 232 (5.5%) | 1873 (18.1%) | 353 (37.6%) | |
| Marital Status | |||||
| Married | 10,440 (67.2%) | 3036 (71.4%) | 6909 (66.8%) | 495 (52.8%) | <0.0001 |
| Never married | 1992 (12.8%) | 425 (10.0%) | 1412 (13.7%) | 155 (16.5%) | |
| Previously married | 1329 (8.6%) | 279 (6.6%) | 884 (8.5%) | 166 (17.7%) | |
| Unknown | 1771 (11.4%) | 511 (12.0%) | 1138 (11.0%) | 122 (13.0%) | |
| Tumour Grade | |||||
| Grade 1–2 | 7562 (48.7%) | 2222 (52.3%) | 4928 (47.6%) | 412 (43.9%) | <0.0001 |
| Grade 3 | 6352 (40.9%) | 1613 (37.9%) | 4331 (41.9%) | 408 (43.5%) | |
| Unknown | 1618 (10.4%) | 416 (9.8%) | 1084 (10.5%) | 118 (12.6%) | |
| ER Status | |||||
| Positive | 10,160 (65.4%) | 2760 (64.9%) | 6797 (65.7%) | 603 (64.3%) | <0.0001 |
| Negative | 3646 (23.5%) | 929 (21.9%) | 2469 (23.9%) | 248 (26.4%) | |
| Unknown | 1726 (11.1%) | 562 (13.2%) | 1077 (10.4%) | 87 (9.3%) | |
| PR Status | |||||
| Positive | 8650 (55.7%) | 2348 (55.2%) | 5788 (56.0%) | 514 (54.8%) | <0.0001 |
| Negative | 5022 (32.3%) | 1301 (30.6%) | 3393 (32.8%) | 328 (35.0%) | |
| Unknown | 1860 (12.0%) | 602 (14.2%) | 1162 (11.2%) | 96 (10.2%) | |
| HER2 Status | |||||
| Negative | 8377 (53.9%) | 2276 (53.5%) | 5581 (54.0%) | 520 (55.4%) | <0.0001 |
| Positive | 3528 (22.7%) | 842 (19.8%) | 2454 (23.7%) | 232 (24.7%) | |
| Unknown | 3627 (23.4%) | 1133 (26.7%) | 2308 (22.3%) | 186 (19.8%) | |
| Surgery | |||||
| Breast Conserving Surgery | 4731 (30.5%) | 1555 (36.6%) | 2977 (28.8%) | 199 (21.2%) | <0.0001 |
| Mastectomy | 8251 (53.1%) | 2002 (47.1%) | 5674 (54.9%) | 575 (61.3%) | |
| No Surgery | 451 (2.9%) | 85 (2.0%) | 327 (3.2%) | 39 (4.2%) | |
| Unknown | 2099 (13.5%) | 609 (14.3%) | 1365 (13.2%) | 125 (13.3%) | |
| Breast reconstructiona | |||||
| Yes | 1293 (15.7%) | 419 (20.9%) | 824 (14.5%) | 50 (8.7%) | <0.0001 |
| No | 6405 (77.6%) | 1455 (72.7%) | 4461 (78.6%) | 489 (85.0%) | |
| Unknown | 553 (6.7%) | 128 (6.4%) | 389 (6.9%) | 36 (6.3%) | |
| Timely Surgery | |||||
| Yes | 12,474 (80.3%) | 3434 (80.8%) | 8306 (80.3%) | 734 (78.3%) | <0.0001 |
| No | 259 (1.7%) | 65 (1.5%) | 169 (1.6%) | 25 (2.7%) | |
| Not needed | 1307 (8.4%) | 272 (6.4%) | 921 (8.9%) | 114 (12.2%) | |
| Not assessable | 1492 (9.6%) | 480 (11.3%) | 947 (9.2%) | 65 (6.9%) | |
| Non-compliance rateb | 2.03% | 1.86% | 1.99% | 3.29% | 0.036c |
| Radiotherapy | |||||
| Yes | 7023 (45.2%) | 1940 (45.6%) | 4705 (45.5%) | 378 (40.3%) | 0.014 |
| No | 749 (4.8%) | 183 (4.3%) | 512 (5.0%) | 54 (5.8%) | |
| Not needed | 4286 (27.6%) | 1143 (26.9%) | 2858 (27.6%) | 285 (30.4%) | |
| Not assessable | 3474 (22.4%) | 985 (23.2%) | 2268 (21.9%) | 221 (23.6%) | |
| Non-compliance rateb | 9.63% | 8.62% | 9.81% | 12.50% | 0.034c |
| Chemotherapy | |||||
| Yes | 6069 (39.1%) | 1457 (34.3%) | 4236 (41.0%) | 376 (40.1%) | <0.0001 |
| No | 1965 (12.7%) | 506 (11.9%) | 1297 (12.5%) | 162 (17.3%) | |
| Not needed | 2339 (15.1%) | 773 (18.2%) | 1459 (14.1%) | 107 (11.4%) | |
| Not assessable | 5159 (33.2%) | 1515 (35.6%) | 3351 (32.4%) | 293 (31.2%) | |
| Non-compliance rateb | 24.50% | 25.78% | 23.44% | 30.11% | 0.0008c |
| Endocrine therapy | |||||
| Yes | 8563 (55.1%) | 2260 (53.2%) | 5781 (55.9%) | 522 (55.7%) | <0.0001 |
| No | 857 (5.5%) | 250 (5.9%) | 561 (5.4%) | 46 (4.9%) | |
| Not needed | 3097 (19.9%) | 797 (18.7%) | 2095 (20.3%) | 205 (21.9%) | |
| Not assessable | 3015 (19.4%) | 944 (22.2%) | 1906 (18.4%) | 165 (17.6%) | |
| Non-compliance rateb | 9.10% | 9.96% | 8.85% | 8.10% | 0.18c |
| Targeted therapy | |||||
| Yes | 1366 (8.8%) | 309 (7.3%) | 974 (9.4%) | 83 (8.8%) | 0.0005 |
| No | 756 (4.9%) | 187 (4.4%) | 520 (5.0%) | 49 (5.2%) | |
| Not needed | 9518 (61.3%) | 2627 (61.8%) | 6321 (61.1%) | 570 (60.8%) | |
| Not assessable | 3892 (25.1%) | 1128 (26.5%) | 2528 (24.4%) | 236 (25.2%) | |
| Non-compliance rateb | 35.63% | 37.70% | 34.81% | 37.12% | 0.47c |
a
Receipt of reconstruction was assessed only amongst patients who received mastectomy.
b
Non-compliance was assessed only amongst patients defined as needing the treatment, i.e. [“No”/(“Yes”+”No”)].
c
The chi square test was conducted between HI-tiers for each treatment modality only amongst patients assessed to need the treatment.
ER: estrogen receptor, PR: Progesterone receptor, HER2: Human epidermal growth factor receptor 2.